Skip to content
Screener

Discontinued — last reported Q2 '26

Total Revenue at other companies

Illumina logo
IlluminaILMN
$1.16B+9.4%
Quanterix Corporation logo
Quanterix CorporationQTRX
$32.91M+34.4%
Revvity logo
RevvityRVTY
$729.69M+1.3%
Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
$110.72M+19.3%
Agilent Technologies logo
Agilent TechnologiesA
$1.84B+10.0%
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
$8.05M+10.9%

Segments

By geography

See full
Americas$17.62M-0.4%
Europe, Middle East and Africa$14.43M+52.4%
Asia-Pacific$6.96M-44.8%

By product

See full
Consumable revenue$20.11M+6.2%
Instrument revenue$12.84M-9.3%
Service and other revenue$6.06M-9.4%

By segment

See full
Reportable Segment$39.01M-1.9%

Other financials

Income statement

See full
Gross profit$12.6M-13.9%
Operating income-$44.6M+0.5%
Net income-$44.7M-6.7%
EPS (diluted)-$0.140.0%

Balance sheet

See full
Cash & equivalents$62.6M+10.5%
Total debt$61.8M+17.1%
Total equity-$33.2M-154%
Total assets$751.9M-8.9%

Cash flow

See full
Operating cash flow-$35.6M-21.1%
CapEx$1.6M+183%
Free cash flow-$37.1M-24.1%

Valuation

See full
Market cap$368.06M-5.6%
Enterprise value$367.25M-4.8%
P/S2.3×-0.2×

Profitability

See full
Gross margin36.4%+15.0pp
Operating margin-83.5%-37.4pp
Net margin-82.5%-35.5pp
FCF margin-77.5%-13.2pp

Returns & leverage

See full
Return on equity-273.6%+314pp
Debt / equity25.1×+24.5×
Current ratio4.9×-2.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Pacific Biosciences of California’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:30 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001299130-26-000122
(In thousands, except per share amounts)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenue:
Product revenue$32,950$33,083$64,484$64,196
Service and other revenue6,0576,68311,70112,723
Total revenue39,00739,76676,18576,919
Cost of Revenue:
Cost of product revenue20,94420,02240,91646,355
Cost of service and other revenue5,2424,8539,4248,631
Amortization of acquired intangible assets1831833664,528

Item 1. Financial Statements (unaudited):

FAQ

What is Pacific Biosciences of California's total revenue?
Pacific Biosciences of California (PACB) reported total revenue of $39.01M in Q2 2026.
How has Pacific Biosciences of California's total revenue changed year-over-year?
Pacific Biosciences of California's total revenue decreased by 1.9% year-over-year, from $39.77M to $39.01M.
What is the long-term trend for Pacific Biosciences of California's total revenue?
Over 4 years (2021 to 2025), Pacific Biosciences of California's total revenue has grown at a 5.2% compound annual growth rate (CAGR), from $130.51M to $160.01M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Pacific Biosciences of California's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude